Trial data show switching between ABP 654 and reference ustekinumab maintains similar psoriasis control, safety, and ...
FDA expands Tofidence uses, Teva launches Eylea biosimilar in Europe, and Alvotech’s Entyvio rival enters FDA review—boosting ...
Italian study finds most MS patients start biosimilars unaware, exposing education gaps and highlighting MS nurses as key to boosting trust and uptake. Most people with multiple sclerosis had never ...
New EULAR guidelines speed RA treatment switches as rheumatoid arthritis biosimilars and biosimilar cost savings push earlier biologics use. The growing availability of biosimilar disease-modifying ...
The FDA has approved ranibizumab-hkdz (Ranluspec; Lupin Limited) as an interchangeable biosimilar for wet AMD, DME, DR, RVO, and mCNV. This article was originally published by Modern Retina. This ...
Evidence shows biosimilars switching in ankylosing spondylitis maintains disease control with biologics, cuts costs, and highlights nocebo risks. Biologic therapy reaches fewer than half of eligible ...
Immgolis and Immgolis Intri have the same indications as Simponi and Simponi Aria, treating patients with rheumatoid arthritis and ulcerative colitis. The biosimilars will be available in the fourth ...
Evidence suggests that adoption of oncology biosimilars in Medicare value-based payment models has produced substantial cost savings and improved provider financial performance. We estimate that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results